BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 9389743)

  • 1. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
    Karanikas V; Hwang LA; Pearson J; Ong CS; Apostolopoulos V; Vaughan H; Xing PX; Jamieson G; Pietersz G; Tait B; Broadbent R; Thynne G; McKenzie IF
    J Clin Invest; 1997 Dec; 100(11):2783-92. PubMed ID: 9389743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
    Karanikas V; Thynne G; Mitchell P; Ong CS; Gunawardana D; Blum R; Pearson J; Lodding J; Pietersz G; Broadbent R; Tait B; McKenzie IF
    J Immunother; 2001; 24(2):172-83. PubMed ID: 11265775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTL in mice immunized with human mucin 1 are MHC-restricted.
    Apostolopoulos V; Loveland BE; Pietersz GA; McKenzie IF
    J Immunol; 1995 Dec; 155(11):5089-94. PubMed ID: 7594517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection.
    Karanikas V; Thynne G; Mitchell P; Ong CS; Gunawardana D; Blum R; Pearson J; Lodding J; Pietersz G; Broadbent R; Tait B; McKenzie IF
    J Immunother (1991); 2001 Mar; 24(2):172-183. PubMed ID: 11449074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
    Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
    J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.
    Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L
    Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
    Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
    Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy.
    Karanikas V; Lodding J; Maino VC; McKenzie IF
    Clin Cancer Res; 2000 Mar; 6(3):829-37. PubMed ID: 10741704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
    Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
    Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1 and breast cancer.
    Apostolopoulos V; Pietersz GA; McKenzie IF
    Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses.
    Tang CK; Sheng KC; Pouniotis D; Esparon S; Son HY; Kim CW; Pietersz GA; Apostolopoulos V
    Vaccine; 2008 Jul; 26(31):3827-34. PubMed ID: 18550230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
    Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
    Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
    Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
    Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.
    Wright SE; Rewers-Felkins KA; Quinlin IS; Fogler WE; Phillips CA; Townsend M; Robinson W; Philip R
    Immunol Invest; 2008; 37(3):215-25. PubMed ID: 18389441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular biological analyses of mucin core proteins and their clinical application].
    Hinoda Y; Imai K
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):150-6. PubMed ID: 8311484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and preclinical evaluation of a Bacillus Calmette-GuĂ©rin-MUC1-based novel breast cancer vaccine.
    Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
    Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.